PREVIOUS
✖
Clinical Trials for Covid
May 1 , 2020
1672 days
911
0
- Germany has approved first clinical trials of a COVID-19 vaccine on humans.
- The German Biotechnology company BioNTech’s vaccine program was authorized for human clinical trials.
- BioNTech and Pfizer are jointly developing BNT162.
- This is the fourth authorized clinical trial worldwide.
- In Britain, volunteers in a trial at the University of Oxford are set to be given the first dose of a potential vaccine.
- It was based on a virus found in chimpanzees.
- Aside from Biontech and Oxford, three other clinical trials on humans have been approved worldwide.
- The Chinese and US developers among the first to move.
- Beijing approved the first trial for a vaccine developed by the military-backed Academy of Military Medical Sciences and Hong Kong based CanSino Bio.
- The US drug developer Moderna already started the trial with the US National Institutes of Health.
- Another US lab, San Diego-based Inovio Pharmaceuticals, also began first phase human trials.
|
Name of Vaccine |
Developer Name |
Current stage of clinical Trials |
Start Date |
|
AD5-NCOV (Adenovirus Type 5 Vector) |
CanSino Biological & Beijing Institute of Biotechnology |
Phase 2 |
10 April |
|
ChAdOx1 |
University of Oxford |
Phase 1/2 |
23 April |
|
INO-4800 DNA plasmid vaccine |
Inovio Pharmaceuticals |
Phase 1 |
3 April |
|
Inactivated |
Beijing Institute of Biological Products |
Phase 1 |
10 April |
|
PiCoVacc (Inactivated + alum) |
Sinovac |
Phase 1 |
13 April |
|
BNT162 mRNA |
BioNTech/Fosun Pharma/Pfizer |
Phase 1/2 |
Approved, not started |
|
LNP-encapsulated mRNA-1273 |
Moderna/NIAID |
Phase 1 |
3 March |
Leave a Reply
Your Comment is awaiting moderation.